RA Capital Management, L.P. is a Boston-based venture capital firm focused on growth capital and early-stage investments in the healthcare and life sciences sectors. Established in 2001, the firm specializes in funding companies involved in drug development, medical devices, diagnostics, and biotechnology. It engages in a range of investment stages, from seed funding to later rounds and public offerings, often preferring to co-invest and take board positions. RA Capital targets companies that are innovating in areas such as prevention, cost-effective diagnostics, genetic testing, and personalized medicine. The firm is staffed by professionals with backgrounds in biology, chemistry, and medicine, providing them with a deep understanding of the scientific and regulatory landscape. This expertise allows RA Capital to identify promising technologies and offer strategic guidance, including potential partnerships and insights into public market demands.

OrbiMed Advisors LLC is a healthcare-focused investment firm founded in 1989, managing approximately $5 billion in assets. The firm specializes in a range of investment strategies, including private equity, venture capital, and public equity, targeting companies across the healthcare spectrum—from startups to large multinational corporations. OrbiMed invests in various sectors within the healthcare industry, including pharmaceuticals, biotechnology, life sciences, medical devices, and health IT. The firm typically invests between $3 million and $150 million, often seeking majority stakes in its portfolio companies. With a global investment approach, OrbiMed operates from offices in New York, San Francisco, Mumbai, Herzliya, Shanghai, West Kowloon, and Luxembourg, focusing on opportunities in North America, Europe, Asia, and Israel. Its investment strategies are underpinned by fundamental analysis, encompassing investments in public equity, fixed income, and alternative markets.

Novo Holdings, established in 1999, is the holding company of the Novo Group, primarily managing the investment assets of the Novo Nordisk Foundation. Based in Copenhagen, with additional offices in San Francisco and Boston, Novo Holdings focuses on two main investment categories: Life Science Investments, which encompasses funding life science companies at various stages of development, and Financial Investments, which entails managing a diversified portfolio of equity and fixed income securities. As a prominent life science investor, Novo Holdings aims to create long-term value while ensuring that the Foundation can distribute returns for scientific, social, and humanitarian purposes to enhance public health and welfare. The company has also developed initiatives such as Novo Seeds, which supports early-stage applied research in life sciences, and invests in later-stage life science companies through growth equity. Novo Holdings maintains a strategic influence over affiliated companies, aligning their operations with the values and objectives of the Novo Group.

Perceptive Advisors LLC is an investment management firm founded in 1999 and headquartered in New York City, with an additional office in Boston. The firm specializes in the healthcare sector, focusing on biotechnology, pharmaceuticals, life sciences, diagnostics, digital health, medical devices, and healthcare services. It engages in venture capital and incubation, investing at various stages of a company's life cycle, including seed and Series A funding, as well as late-stage venture and public market investments. Perceptive Advisors employs a long/short equity strategy and utilizes hedging techniques, including equity options and index options, while conducting in-house research to inform investment decisions. The firm also manages separate client-focused equity portfolios and provides customized debt financing solutions through its Perceptive Credit Opportunities Fund. Its clientele includes institutional investors, financial institutions, investment funds, and high-net-worth individuals.

SOSV is a global venture capital firm founded in 1995 and headquartered in Princeton, New Jersey. Specializing in seed-to-growth stage investments, SOSV operates multiple accelerator programs worldwide, including HAX for hardware, IndieBio and RebelBio for life sciences, Chinaccelerator and MOX for cross-border internet ventures, Food-X for innovative food solutions, and dlab for blockchain technology. The firm focuses on investments in revolutionary deep technologies aimed at improving human and planetary health, as well as cross-border markets, particularly in Asia. SOSV invests in approximately 150 startups annually, providing support through its resources to accelerate product development and scaling. Over its two-decade history, SOSV has established a strong reputation, consistently ranking among the top venture capital firms globally.

5Y Capital is a private equity and venture capital firm based in Shanghai, China, specializing in seed, startup, early venture, and growth capital investments. Established in 1992, the firm focuses on a diverse range of sectors, including healthcare, technology, fintech, internet services, consumer services, media, and life sciences, among others. It aims to support entrepreneurs in building innovative companies, particularly in China and other emerging markets in Asia/Pacific. Managing approximately USD 5 billion in dual-currency funds, 5Y Capital attracts investments from global sources, including sovereign wealth funds and family offices. The firm typically makes initial investments exceeding USD 500,000 per portfolio company. 5Y Capital operates under the Morningside Group, which is committed to socially responsible investing, particularly in educational opportunities and scientific research.

Invus Financial Advisors, LLC is an employee-owned hedge fund sponsor based in New York, specializing in investments across various stages including special situations, venture capital, and growth equity. Founded in 2006, the firm manages over $4 billion in an evergreen fund and operates additional offices in London, Paris, and Hong Kong. Invus focuses on making minority investments and often acts as a lead investor or part of a consortium, emphasizing a flexible approach tailored to the unique needs of each company. The firm has a long-standing commitment to empowering owner-managers, aligning its incentives with those of its partners, and recognizing that meaningful business transformation requires time and resilience. With a history of reinvesting capital from European families since its inception, Invus demonstrates a dedication to fostering long-term relationships and navigating challenges in pursuit of extraordinary performance.

New Enterprise Associates, Inc. is a private equity and venture capital firm established in 1977 and headquartered in Menlo Park, California, with additional offices in India and China. The firm specializes in investments across various stages of company development, including seed, start-up, early stage, and later stage, with a focus on sectors such as information technology, healthcare, and energy technology. NEA's investment strategy encompasses a wide range of industries, including consumer internet, software, biotechnology, medical devices, and alternative energy. With over $19 billion in cumulative committed capital, the firm has a notable track record, having participated in more than 210 portfolio company IPOs and over 360 acquisitions. NEA aims to invest between $0.05 million and $20 million, targeting both domestic and international markets, particularly in Asia and the Americas.

Wellington Management Company LLP, founded in 1928 and headquartered in Boston, Massachusetts, is a prominent investment management firm providing comprehensive solutions to institutional clients worldwide. The firm specializes in a diverse range of investment strategies, including equity, fixed income, multi-asset, and alternative investments, tailored to meet the unique return and risk objectives of its clients. Wellington Management employs a collaborative approach, leveraging proprietary research and analytical tools to identify opportunities and manage risks across global capital markets. The firm caters to a wide array of clients, including sovereign institutions, endowments, foundations, wealth managers, and insurance companies, spanning more than 50 countries. With a focus on long-term investment principles, Wellington Management fosters independent thought and debate within its teams, ensuring that resources are effectively utilized to deliver consistent results. The firm also emphasizes environmental, social, and governance (ESG) considerations in its research and investment processes, engaging with companies on key ESG topics.

Versant Ventures is a prominent healthcare investment firm headquartered in California, specializing in medical devices, biotechnology, and pharmaceuticals. Established in 1999, the firm manages approximately $2.3 billion and invests across all stages of company development, with a strong focus on discovering and developing innovative therapeutics. Versant has a global presence with offices in Canada, the U.S., and Europe, and its team comprises professionals with extensive investment, operational, and scientific expertise, allowing for a proactive approach to building companies. Since its inception, Versant has successfully facilitated the growth of over 65 companies, leading to numerous acquisitions and public offerings.

Janus Henderson Group plc is a global asset management firm based in London, with additional offices in Jersey and Sydney. Founded in 1934, the company provides a range of investment services to institutional, retail, and high net worth clients. It manages client-focused equity and fixed income portfolios, as well as equity, fixed income, and balanced mutual funds. The firm invests in public equity and fixed income markets, along with real estate and private equity opportunities. As of March 2018, Janus Henderson manages approximately £265.3 billion in assets and employs over 2,000 staff worldwide, dedicated to helping clients achieve their long-term financial objectives.

ARCH Venture Partners, L.P. is a private equity and venture capital firm founded in 1986 and based in Chicago, Illinois, with additional offices across North America and South America. The firm specializes in early-stage and growth capital investments, primarily focusing on life sciences and biotechnology, but also covering a wide array of technology sectors such as advanced materials, communications technologies, and information technology. ARCH is recognized for its role in commercializing innovations developed at academic research institutions and national laboratories. It has raised over $3 billion through ten venture funds and has invested in more than 150 companies, often co-founding them with leading scientists and entrepreneurs. The firm typically invests between $50,000 and $150 million per company, aiming to enter at seed rounds to minimize risk, and seeks a seat on the Board of Directors for its portfolio companies. While primarily investing in the United States, ARCH also targets opportunities in Canada, Europe, and select countries in Asia, focusing on underserved geographic markets rich in scientific research and technological talent.

Samsara BioCapital LLC is a private equity firm established in 2016 and located in Palo Alto, California. The firm specializes in investing in biotechnology companies across the United States, providing capital and strategic support to help advance innovations in the life sciences sector. Samsara BioCapital aims to identify and cultivate promising biotechnological advancements that can transform healthcare and improve patient outcomes.

Alexandria Venture Investments, LLC is a venture capital firm established in 1996 and headquartered in Pasadena, California. As the strategic investment arm of Alexandria Real Estate Equities, it focuses on providing capital to seed, early-stage, and growth-stage companies within the healthcare sector. The firm emphasizes investments in biopharma, diagnostics, life sciences, research tools, agrifoodtech, and agtech. Alexandria Venture Investments aims to support innovative entities developing breakthrough technologies and therapies, leveraging its extensive industry knowledge and relationships with leading investors. Its approach is characterized by a commitment to fostering innovation and entrepreneurship in the life sciences and technology sectors.

Qiming Venture Partners is a prominent venture capital firm established in 2006 and headquartered in Shanghai, with additional offices in Beijing, Suzhou, and Hong Kong. The firm specializes in investing in early to growth-stage companies across various sectors, including media and internet, information technology, consumer and retail, healthcare, and clean technology in China. Since its inception, Qiming has built a reputation as a leading investment firm in the region, managing multiple funds with over $1 billion in assets. The firm aims to support promising entrepreneurs and innovative businesses, contributing to the development of China's dynamic economic landscape.

Pfizer is one of the largest pharmaceutical companies in the world, founded in 1849 and headquartered in the United States. The company is dedicated to improving health and well-being by applying scientific advancements and global resources. Pfizer manufactures and sells a diverse range of healthcare products, primarily focusing on prescription drugs and vaccines, which account for the majority of its sales. Notable products include the pneumococcal vaccine Prevnar 13, the cancer treatment Ibrance, and the cardiovascular drug Eliquis. With annual sales nearing $50 billion, Pfizer has a strong international presence, with nearly half of its sales derived from global markets, particularly emerging economies. The firm is committed to providing access to safe, effective, and affordable medicines to enhance patient outcomes and address pressing healthcare challenges.

GV Management Company, LLC, established in 2009 as the venture capital arm of Alphabet Inc., specializes in investments across various stages, including seed, early, and late-stage funding. Based in Mountain View, California, with additional offices in Boston, New York, Seattle, Cambridge, and London, GV focuses on sectors such as life sciences, healthcare, artificial intelligence, robotics, transportation, cybersecurity, and agriculture. The firm has invested in over 300 companies, aiming to drive innovation and improve lives. GV seeks to make investments of up to $50 million, while offering early-stage startups funding of up to $250,000, typically taking minority stakes in these companies. Through its extensive network, GV provides startups with unique access to technology and talent, enhancing their potential for success.

Bpifrance Financement S.A. is a French financial institution that provides a range of financing solutions and support services aimed at fostering the growth of startups, small and medium-sized enterprises (SMEs), and mid-cap companies. It offers various financial products, including medium to long-term loans, export insurance, and leasing options for both tangible and intangible assets. Additionally, Bpifrance supports companies through consulting services, guarantees for bank financing, and training for executives. The organization also engages in direct investments and manages funds aimed at enhancing the financial landscape for businesses at different stages of their development. Established in 1980 and based in Maisons-Alfort, France, Bpifrance was formerly known as OSEO S.A. and rebranded in July 2013. It operates as a subsidiary of Bpifrance SA, reinforcing its commitment to bolstering the French economy through diversified financial solutions.

Vivo Capital, LLC is a private equity and venture capital firm established in 1996 and headquartered in Palo Alto, California, with additional offices in Asia. The firm specializes in investing in healthcare sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services, primarily focusing on companies in the United States and East Asia. Vivo Capital manages approximately $5.8 billion in assets and has invested in over 290 public and private companies globally. The firm employs a multi-fund investment strategy, targeting various financing stages from early-stage ventures to public companies, and typically invests between $2 million and $40 million. Vivo Capital's team consists of more than 50 professionals with diverse expertise in medical, scientific, and entrepreneurial fields, allowing the firm to identify and nurture high-quality companies within the healthcare industry.

Polaris Partners is a venture capital firm founded in 1996 and headquartered in Boston, Massachusetts. With a focus on technology and healthcare sectors, Polaris invests in companies at all stages of development, from inception to profitable growth. The firm has a history of partnering with experienced entrepreneurs and innovators, aiming to enhance the way people live and work. In addition to its Boston headquarters, Polaris has offices in San Francisco and New York, and it actively targets investments in life sciences, biotechnology, and software industries across the United States and Europe. Over its more than two-decade history, Polaris Partners has established itself as a multibillion-dollar investment firm committed to fostering innovation and entrepreneurship.

The Redmile Group, established in 2007 and based in San Francisco with an additional office in New York, is a private equity firm specializing in venture capital investments within the healthcare sector. The firm manages multiple funds, including Redmile Biopharma Investments II and III, which focus specifically on the biopharma industry. Redmile Group aims to identify and support innovative healthcare companies, leveraging its expertise to foster growth and development in this critical field.

Sofinnova Partners is an independent venture capital firm headquartered in Paris, France, with a focus on the life sciences sector, including biopharmaceuticals, biotechnology, medical devices, and industrial biotechnology. Over its 45-year history, the firm has financed nearly 500 companies, primarily targeting start-ups, early-stage ventures, corporate spin-offs, and occasional turnaround situations. Sofinnova Partners actively sources investment opportunities and often serves as the first institutional investor in Series A financings, taking a lead role in its portfolio companies. The firm engages closely with entrepreneurs from the formation phase, holding board positions and guiding companies through their development until exit. While primarily investing throughout Europe, Sofinnova Partners also allocates a portion of its investments globally.

Frazier Healthcare VI, managed by Frazier Healthcare Partners, is a private equity and venture capital fund based in Seattle, Washington. Founded in 1991, the firm specializes in providing growth equity financing to healthcare companies. Frazier invests across a range of stages, from early-stage ventures to established businesses, focusing on sectors such as pharmaceuticals, biotechnology, medical products, and healthcare services. The firm typically invests between $3 million and $100 million, targeting companies with EBITDA of $10 million to $75 million. It takes an active role in its investments, often acting as a lead investor and securing board representation. Frazier seeks to address unmet medical needs through innovative therapeutics and has invested in over 170 healthcare companies to date, leveraging its extensive network and expertise in the industry. The firm primarily operates in the United States, Canada, and Europe, with a keen interest in regions like the Bay Area, San Diego, Seattle, Boston, and North Carolina.

F Prime, Inc. is a venture capital firm based in Cambridge, Massachusetts, with additional offices in San Francisco and London. Founded in 1969, it is part of the legacy of Fidelity Investments, one of the largest asset management firms in the world. F Prime focuses on investing in North American and European companies across various sectors, including healthcare, life sciences, medtech, technology, and health information technology. The firm operates several specialized funds, such as those dedicated to healthcare and life sciences, which aim to support early-stage companies in these industries. With a commitment to fostering entrepreneurship, F Prime leverages its extensive insights, domain expertise, and relationships to assist entrepreneurs in building impactful companies, all while avoiding the pressures of external fundraising.

Atlas Venture L.P. is a private equity and venture capital firm based in Cambridge, Massachusetts, founded in 1980. The firm specializes in early-stage investments, primarily in the life sciences and technology sectors. In life sciences, Atlas Venture focuses on biotechnology, therapeutics, medical technologies, and personalized medicine. In technology, it targets areas such as fintech, consumer innovation, and emerging web services. The firm employs a seed-led venture creation strategy that emphasizes rigorous selection of promising startups led by capable entrepreneurs. Atlas Venture typically invests between $500,000 and $5 million in its portfolio companies, often taking the lead role and seeking board representation. The firm manages over $2 billion in committed capital and has been involved with more than 350 companies across various countries. Its investment strategy prioritizes opportunities in the United States, particularly in regions such as New England and California.

Logos Capital is an equity hedge fund manager based in San Francisco, California, founded in March 2019. The firm specializes in fundamental biotechnology investments, leveraging both in-house data analytics and scientific expertise to identify transformative therapies in healthcare. By combining medical, scientific, and statistical disciplines, Logos enhances its investment diligence to uncover compelling opportunities with uncorrelated market returns. The firm's approach integrates statistical modeling of clinical trials with rigorous scientific assessment, aiming to achieve high conviction in its investment positions. Logos Capital manages pooled investment vehicles and focuses on public equity markets, employing a blend of internal research and external insights to inform its investment strategies.

Lilly Asia Ventures, established in 2008 and based in Shanghai, China, serves as the corporate venture capital arm of Eli Lilly and Company. The firm focuses on making investments in the life sciences and healthcare sectors, primarily targeting opportunities in China but also considering ventures in other parts of East and South Asia. Lilly Asia Ventures seeks to invest in companies at various stages, from seed to later stages, with a preference for those showcasing strong management teams and innovative technologies or business models. The investment strategy emphasizes human therapeutics, medical technology, healthcare services, and broader life sciences. Typically, investments range from $5 million to $15 million per round, with an inclination towards acquiring minority stakes, usually under 20 percent. The firm aims to play an active role in its portfolio companies by seeking board seats or observation rights.

Boxer Capital LLC is a venture capital firm founded in 2005 and based in the United States. The firm specializes in investing in both early-stage and late-stage biotechnology companies, focusing on the entire drug development lifecycle, from preclinical discovery to clinical and commercial stages. Boxer Capital targets private and public companies within the biotechnology sector, providing capital to support their growth and development. It operates as a subsidiary of Tavistock Life Sciences, leveraging its resources and expertise to foster innovation in the biotechnology field.

Fidelity Investments is a privately owned investment manager based in Boston, Massachusetts, founded in 1946. The firm offers a wide range of financial services, including individual retirement accounts, 401(k) rollovers, annuities, discount brokerage, and wealth management. It serves a diverse clientele, including individual investors, businesses, financial advisors, and institutions. Fidelity manages equity, fixed income, and balanced mutual funds, investing in public equity and fixed income markets worldwide. The firm conducts in-house research to guide its investment decisions and supports over 32 million clients in achieving their financial goals. Additionally, Fidelity assists more than 22,000 businesses with employee benefit programs and collaborates with over 13,000 financial institutions to provide innovative investment and technology solutions.

RTW Investments, LP is an employee-owned hedge fund manager based in New York, established in 2009. The firm specializes in a sector-oriented investment strategy, focusing primarily on the life sciences, big data, and digital health sectors in the United States and Europe. RTW Investments manages pooled investment vehicles and also offers separate client-focused equity and fixed income portfolios, including equity mutual funds. The firm emphasizes fundamental research and conducts in-house analyses to inform its investment decisions, aiming to capitalize on opportunities in both public equity and fixed income markets globally.

Eli Lilly and Company, founded in 1876, is a prominent American pharmaceutical firm engaged in the discovery, development, manufacture, and sale of a wide range of pharmaceutical products. The company operates facilities in the United States, Puerto Rico, and 25 other countries, distributing its products in approximately 135 countries worldwide. Eli Lilly's product portfolio includes treatments for various medical conditions, particularly in the fields of neurosciences and endocrinology. Notable products include Zyprexa for schizophrenia and bipolar disorder, Cymbalta for depression and anxiety, and Humalog for diabetes management. In addition to its pharmaceutical business, Eli Lilly also conducts research aimed at improving animal health and food production efficiency. The Eli Lilly Foundation further supports community initiatives focused on enhancing patient outcomes and educational opportunities, particularly in underserved areas.

Deerfield is an investment management firm established in 1994 that specializes in advancing healthcare through investment, information, and philanthropy. With over $8 billion in funds, Deerfield invests broadly in both public and private healthcare sectors, targeting a diverse range of companies from early-stage drug research to established healthcare services and medical device firms. The firm typically maintains equity or debt interests in more than 100 companies. It employs the Deerfield Institute, which conducts extensive research to provide objective market intelligence, engaging with thousands of professionals annually to address complex healthcare challenges. Additionally, a portion of the firm's profits is allocated to the Deerfield Foundation to support various philanthropic initiatives.

Casdin Capital, LLC is an investment firm specializing in the life sciences and healthcare sectors. Founded in 2012 by Eli Casdin, who serves as the Chief Investment Officer, the firm employs a fundamental research approach to manage a long-short equity fund. Casdin Capital invests across a spectrum of opportunities, ranging from early-stage to late-stage private investments. As of October 2020, the firm manages approximately $2.2 billion in assets.

EcoR1 Capital, LLC is an employee owned hedge fund sponsor. The firm provides its services to pooled investment vehicles. The firm also manages separate client-focused equity and fixed income portfolios. The firm invests in the public equity markets of the United States. It employs long/short strategy to make its investments. The firm typically invests in companies in biotechnology sector. EcoR1 Capital, LLC was founded in 2012 and is based in San Francisco, California.

Novartis Venture Fund, established in 1996 and based in Basel, Switzerland, specializes in venture capital investments within the healthcare sector, particularly focusing on biotechnology and biopharma. The fund targets the development of novel therapeutics, medical devices, diagnostics, and drug delivery systems, prioritizing investments that address unmet medical needs and demonstrate significant clinical impact. Initial investments typically range from USD 100,000, with total funding potentially reaching USD 30 to 50 million over the lifespan of a company. Novartis Venture Fund emphasizes early-stage investments to foster company growth and is open to leading or co-leading deals, as well as participating in larger syndicates. Its investment strategy encompasses regions including the USA, Canada, Europe, and Asia-Pacific, with a keen interest in innovative science and experienced management teams.

The Bill & Melinda Gates Foundation is a prominent grant-making organization co-founded by Bill and Melinda Gates in 2000, headquartered in Seattle, Washington, with additional offices in Washington, D.C.; New Delhi, India; Beijing, China; and London, United Kingdom. The foundation focuses on improving global health, enhancing education, and providing support to at-risk families, particularly in the Pacific Northwest. It actively promotes strategies that assist low-income families and works towards greater equality in various sectors. The foundation is also involved in investment management, overseeing an endowment that includes a diverse portfolio primarily in public equity and fixed income markets, while excluding tobacco-related investments. Its trustees include Bill Gates, Melinda Gates, and Warren Buffett.

Canaan VII is an early-stage venture capital fund managed by Canaan Partners, a global firm established in 1987 and based in San Francisco, California. The fund focuses on investing in the software and technology, media, and telecommunications (TMT) sectors within the United States. Canaan Partners manages a diverse portfolio with over 190 exits and has invested in more than 250 companies across various industries, including fintech, healthcare, and digital health. The firm employs a team of experienced investment professionals who seek to support visionary entrepreneurs with innovative ideas, providing capital ranging from $1 million to $20 million across different stages of development. With approximately $5 billion under management across multiple funds, Canaan Partners continues to play a significant role in fostering growth within the technology and healthcare landscapes.

Adage Capital Management is a Boston-based $8.9B Money Management firm focused on managing S&P 500 assets predominantly for Endowments and Foundations such as Harvard University, Northwestern University, Dartmouth College, the American Red Cross and the Getty Foundation. Adage and its predecessor, the Select Equity Group at the Harvard Management Company, has outperformed the S&P index in each of the last 15 years by an average of 3.5%. The fund is run by Phill Gross, who prior to founding Adage, was a Healthcare and Retail analyst, equity research director and partner at the Harvard Management Company for 18 years..

5AM Ventures is a venture capital firm founded in 2002 and headquartered in San Francisco, California, with an additional office in Boston. The firm specializes in seed- and early-stage investments, focusing on companies within the life sciences, healthcare, and technology sectors. Its investment portfolio includes firms involved in biopharmaceuticals, medical technology, drug delivery technologies, and research instruments. 5AM Ventures is recognized for its commitment to fostering innovation in advanced life science technologies.

Sequoia Capital is a prominent venture capital firm founded in 1972 and based in Menlo Park, California. The firm specializes in investing across various stages of startups, including seed, early, and growth stages, and focuses on sectors such as technology, healthcare, financial services, internet, and mobile. Sequoia typically invests between $100,000 and $1 million in seed companies, $1 million to $10 million in early-stage ventures, and $10 million to $100 million in growth investments. The firm operates globally, with significant activities in regions like Israel, China, and India, where it partners with dynamic founders to build successful companies. Sequoia's extensive portfolio includes notable firms and offers valuable insights and resources, benefiting from decades of experience in the venture capital landscape.

T. Rowe Price is a publicly owned investment management firm founded in 1937 and headquartered in Baltimore, Maryland. The company serves a diverse clientele that includes individuals, institutional investors, retirement plans, and financial intermediaries. T. Rowe Price offers a wide array of investment strategies encompassing equity, fixed income, and private equity, with a particular focus on funding technology startups. The firm employs a combination of fundamental and quantitative analysis to guide its investment decisions, utilizing both in-house and external research. Additionally, T. Rowe Price is committed to socially responsible investing, prioritizing environmental, social, and governance factors. With a global presence, the firm operates offices in numerous locations worldwide, enhancing its ability to navigate various markets and deliver reliable investment solutions.

Johnson & Johnson Innovation - JJDC, established in 1973 and based in New Brunswick, New Jersey, serves as the corporate venture capital arm of Johnson & Johnson. The organization focuses on identifying transformative ideas and nurturing them into viable solutions for patients. JJDC targets investments in companies within the pharmaceuticals, medical devices, consumer healthcare, and medtech sectors, aiming to foster innovation that addresses current healthcare challenges. By supporting emerging companies, JJDC plays a crucial role in advancing healthcare solutions and enhancing patient outcomes.

HBM Healthcare Investments is a principal investment firm established in 2001 and based in Zug, Switzerland, with a focus on the biotechnology, human medicine, diagnostics, and medical technology sectors. The firm invests globally in approximately 40 mature emerging companies, primarily targeting private firms that demonstrate significant value creation potential. Approximately two-thirds of its portfolio consists of investments in unquoted companies, while the remainder includes public companies and funds. HBM Healthcare Investments has developed a distinctive market position through its strategic investments in firms whose products are either at advanced stages of development or already available in the market. This diversified approach allows the firm to leverage opportunities across Europe, Asia, and North America, contributing to its broad shareholder base and enhancing its investment capabilities.

Khosla Ventures is a venture capital firm established in 2004 by Vinod Khosla, a co-founder of Sun Microsystems. Based in Menlo Park, California, the firm manages over $5 billion and primarily invests in early-stage technology companies throughout the United States. Khosla Ventures provides capital, strategic advice, and venture assistance to entrepreneurs focused on breakthrough innovations across various sectors, including consumer technology, enterprise solutions, health, education, agriculture, and sustainable energy. The firm has a particular interest in high-risk, high-reward opportunities, often acting as a sole investor in "science or innovation experiments." Investment sizes typically range from $100,000 to over $20 million, allowing Khosla Ventures to support both traditional ventures and unconventional projects.

Nextech Invest is a venture capital and private equity firm based in Zurich, Switzerland, with a focus on early, mid-stage, and late-stage investments in healthcare and life sciences. Founded in 1998, the firm specializes in oncology, targeting companies that develop cancer drugs and diagnostics. It invests in projects that have demonstrated efficacy in preclinical animal models or possess viable device prototypes. Nextech Invest is particularly interested in interdisciplinary technical and scientific initiatives, including therapies, diagnostics, and medical technologies. The firm typically invests between CHF 1 million and CHF 5 million per financing round and aims for a board position in its portfolio companies. It seeks to exit investments within three years, primarily through trade sales. Nextech Invest considers opportunities globally, with a specific interest in companies based in Africa, the Middle East, Asia, North America, and Europe, including Switzerland and Germany.

The Column Group LLC is a venture capital firm based in San Francisco, specializing in early-stage investments in biotechnology companies. Founded in 2005, the firm focuses on the drug discovery and development sector, targeting areas such as cancer, inflammation, infectious disease, metabolic disorders, cardiovascular disease, and nervous system disorders. The Column Group typically invests between $15 million and $30 million per deal, providing support throughout the development process, from initial seed financing to later-stage commercialization. With a commitment to fostering innovation in the pharmaceutical and biotechnology sectors, the firm aims to create the next generation of impactful biotechnology companies.

EQT is a private equity firm headquartered in Stockholm, Sweden, with additional offices across Europe, North America, and the Asia Pacific region. Established in 1994, the firm specializes in buyouts, expansion capital, and infrastructure investments, focusing on mid-market companies in sectors such as healthcare, technology, industrials, and services. EQT employs a responsible ownership approach and an industrial growth strategy, seeking opportunities in regions with significant growth potential, including Northern and Eastern Europe, Asia, and the United States. The firm invests through various strategies, including private capital, real assets, credit, and public value, and aims to acquire controlling or co-controlling stakes in its portfolio companies, often holding investments for four to eight years. EQT Life Sciences, a notable segment of the firm, targets innovative healthcare and life sciences companies.

Foresite Capital is a multi-stage investment firm specializing in healthcare and life sciences, managing approximately $2 billion in assets. The firm employs a rigorous, data-driven approach to investment analysis and collaborates closely with its portfolio companies, offering a diverse team of scientists, engineers, analysts, and clinicians. This collaborative model enables Foresite Capital to understand the distinct business models within the healthcare sector. The firm focuses on addressing significant unmet clinical needs by investing in promising healthcare and life sciences enterprises across various stages of development. Additionally, Foresite Capital prioritizes companies that leverage data science and machine intelligence to innovate within the healthcare landscape. The firm is headquartered in San Francisco, with an additional office in New York.

Forbion Capital Partners is a Netherlands-based venture capital firm established in 2006 that specializes in early-stage investments in life sciences and MedTech companies addressing significant medical needs. With a team of nine investment professionals, Forbion has developed a strong track record since the late 1990s, backing successful companies such as Rhein Biotech, Crucell, and Acorda. The firm currently manages assets exceeding €400 million, distributed across three active funds, including the recently launched Forbion Ventures Fund VI. Additionally, Forbion co-manages BioGeneration Ventures, an early-stage fund focused on academic spin-outs and seed investments within the Netherlands.

MPM Capital is a healthcare investment firm founded in 1996 and headquartered in Cambridge, Massachusetts, with additional offices in Brisbane, California. The firm specializes in early-stage investments in the biotechnology, healthcare, and life sciences sectors, focusing primarily on innovative therapeutic technologies in oncology, immunology, and neuroscience. MPM Capital invests in both private and public companies, targeting areas such as medical technology, specialty pharmaceuticals, and diagnostics. The firm engages in seed and early-stage financing, as well as late-stage investments in biopharmaceuticals with clinical proof-of-concept data. MPM Capital typically invests between $5 million and $50 million and aims to be a lead investor, often taking interim operating positions within its portfolio companies. Its global investment strategy emphasizes North America, Western Europe, and Asia, particularly India, with a commitment to translating scientific advancements into effective medical solutions that improve patient outcomes.